Can a Pre-Procedure painkiller ease the pain of lung nodule marking?
NCT ID NCT07675473
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether giving the painkiller parecoxib before a CT-guided wire placement can reduce pain during lung nodule localization for surgery. About 150 adults with lung cancer scheduled for video-assisted thoracoscopic surgery will receive either parecoxib or a placebo before the wire placement. Researchers will also explore the best timing for the medication to maximize pain relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- parecoxib sodium
- What this could lead to
- If effective, this could establish a simple, non-opioid pain relief strategy for patients undergoing lung nodule localization before surgery.
- What could go wrong
- This is a single-center, Phase 4 trial with 150 participants, so results may not apply broadly. The placebo group also receives no active painkiller, so pain differences may be small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntarily agreed to participate in the study and signed the informed consent form approved by the Ethics Committee. * Male or female adult patients aged 18 years or older. * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) scheduled for Video-Assisted Thoracoscopic Surgery (VATS). * Requires preoperative CT-guided hook wire localization of lung nodules. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * American Society of Anesthesiologists (ASA) physical status classification of I or II. * Fully conscious with no psychiatric or neurological disorders, and capable of fully understanding and correctly using the Visual Analog Scale (VAS) for pain assessment. Exclusion Criteria: * Known history of hypersensitivity to parecoxib sodium, other COX-2 inhibitors, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs). * History or presence of active peptic ulcer disease, gastrointestinal bleeding, or gastrointestinal perforation. * Severe cardiovascular diseases, including but not limited to unstable angina, history of myocardial infarction within the past 6 months, severe arrhythmias, or poorly controlled hypertension. * Coagulation disorders with a bleeding tendency (e.g., hemophilia) or currently receiving full-dose anticoagulation therapy, which the investigator believes may significantly increase the bleeding risk of the hook wire localization. * Severe, uncontrolled pulmonary diseases (e.g., severe chronic obstructive pulmonary disease \[COPD\], interstitial pneumonia) that the investigator believes pose an unacceptable risk for the procedure. * Currently using other analgesic medications that cannot be discontinued during the study period. * Any other conditions that, in the investigator's judgment, might interfere with the outcome assessment or increase the risk to the subject.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung nodules are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?
- Two-Drug combo takes aim at Hard-to-Treat lung cancer